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Identity 
Other names: BPR; MGC120313; MGC120314; 
MGC120315 
HGNC (Hugo): BCL2L12 
Location: 19q13.3 
Local order: Telomere to centromere. 
DNA/RNA 
Description 
Spanning 8.8 kb of genomic DNA, the BCL2L12 gene 
consists of 6 introns and 7 exons. 
Transcription 
The BCL2L12 gene has three splice variants with 
differences in exon 3. The predominant form is 1855 bp 
and encodes the full-length protein. The second splice 
variant lacks exon 3, which consists of 143 bp, thus 
resulting in no ORF. The third splice variant lacks 3 bp 
at the beginning of exon 3 and encodes a protein having 
one amino acid residue less than the full-lengh protein. 
Pseudogene 
Not identified so far. 
Protein 
Description 
The BCL2L12 protein is composed of 334 amino acids, 
with a calculated molecular mass of 36.8 kDa and an 
isoelectric point of 9.45. The BCL2L12 protein 
contains one BH2 and one putative BH3 domain, one 
proline-rich region similar to the TC21  
 
 
protein, and five consensus PXXP tetrapeptide 
sequences. 
BCL2L12 protein also includes various putative 
posttranslational modification sites. There are 
numerous potential sites for O-glycosylation. 
Furthermore, several possible sites of phosphorylation 
have been identified for cAMP-dependent protein 
kinase, protein kinase C, and casein kinase 2.  
In addition, several N-myristoylation sites have been 
predicted. The BCL2L12 protein was found to have 
proline-rich sites. One PPPP site as well as five PP 
amino acid sites are present in this protein. Eight 
putative PXXP motifs were also identified. Proline-rich 
motifs are characterized by the presence of the 
consensus PXXP tetrapeptide, found in all proline-rich 
proteins identified to date. It is known that SH3 
domains recognize proline-rich sequences and that all 
known SH3-binding proteins contain proline-rich 
regions with at least one PXXP motif. Proline-rich 
domains have been identified in a number of diverse 
proteins such as epidermal growth factors, 
phosphatidylinositol 3-kinase, and, more recently, the 
small GTPase RRAS protein and members of the 
RRAS superfamily such as the TC21 protein. 
Moreover, the amino acid loop (PPSPEP) at positions 
271-276 of the BCL2L12 protein is identical with the 
PXXP motif present in the RRAS and TC21 
oncogenes. This motif is required for integrin 
activation. 
The splice variant BCL2L12-A is expected to encode a 
truncated protein of 176 amino acids with five PP 
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Expression 
High levels of BCL2L12 expression are typically found 
in glandular epithelia in various organs, such as 
gastrointestinal tract and/or breast. Lower BCL2L12 
protein expression has been found in prostate tissue. 
Function 
BCL2L12 is involved in apoptosis. However, its 
proapoptotic or antiapoptotic role in different types of 
cells and conditions remains unclear. 
Homology 
Human BCL2L12 shares 98% and 96% identity with 
chimpanzee and Rhesus monkey Bcl2l12, respectively, 
and 83% identity with rat/mouse Bc2l12 as well. 
Mutations 
Note 
No germinal or somatic mutations are identified to be 
associated with cancer so far. 
Implicated in 
Human Leukemias, Solid Tumors 
Note 
Significant alterations of BCL2L12 mRNA expression 
have been noticed in HL-60 leukemia cells as well as in 
MCF7 breast cancer cells, after treatment with various 
antineoplastic agents including cisplatin, carboplatin, 
doxorubicin, methotrexate, and etoposide. These 
important modulations of BCL2L12 mRNA levels 
seem to depend on both the apoptotic inducer and the 
specific apoptotic pathway, implying a strong 
relationship between alterations in BCL2L12 mRNA 
levels and apoptosis.  
Expression analysis of the BCL2L12 gene has showed 
that BCL2L12 mRNA expression may be considered as 
a new prognostic marker for breast cancer, as breast 
tumours of lower stage or grade are more often 
BCL2L12-positive. Moreover, breast cancer patients 
with BCL2L12 mRNA expression are less likely to 
relapse or die, in comparison with BCL2L12-negative 
patients. Regarding BCL2L12 gene expression in colon 
cancer, the BCL2L12-A transcript is overexpressed in 
cancer tissues as compared to their normal mucosa 
counterparts. BCL2L12-A mRNA expression is also 
associated with colon cancer progression, since it is 
usually greater in patients being at the initial stages of 
the disease or having negative nodal status. BCL2L12 
were found also to inhibit post-mitochondrial apoptosis 
signaling in glioblastoma. 
Cytogenetics 
No cytogenetic abnormalities are identified so far. 
Hybrid/Mutated gene 
Not identified so far. 
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